Unfortunately, this study demonstrates that the basal overexpression of phospho-EGFR, along with the overexpression of phospho-AKT and phospho-MEK1, surrogate markers of the EGFR- pathways activation in tumors, are not sufficient to predict this “EGFR-addiction” in oligodendrogliomas. The gene discussed is AKT1; the disease is oligodendroglioma.